US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Organon & Co.

< Previous 1 2 3 Next >
News headline image
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Second Quarter Ended June 30, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the First Quarter Ended March 31, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report First Quarter and Host Conference Call on May 4, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
From Organon & Co.
Via Business Wire
Tickers OGN
News headline image
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
Tickers OGN
< Previous 1 2 3 Next >